Juniper Biologics
Juniper Biologics is a Singapore-based biopharmaceutical company developing novel therapies in oncology, rare diseases, and osteoarthritis, with its current core asset being a gene therapy for knee osteoarthritis acquired from Kolon Life Science.
- Company typePrivate
- Founded-
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Juniper Biologics does
Juniper Biologics is a Singapore-based, privately held biopharmaceutical company focused on developing and commercializing novel therapies across oncology, rare/orphan diseases, and osteoarthritis. The company's stated therapeutic focus spans three distinct verticals, though its current operational footprint centers on a single asset: a gene therapy for knee osteoarthritis in-licensed from Kolon Life Science in April 2022 via a $600 million transaction. This acquisition represents the company's primary product offering and its entry into gene therapy for degenerative musculoskeletal conditions.
The company operates with a small team of 11-50 employees and is led by CEO Raman Singh. Its core technology is gene therapy, specifically applied to musculoskeletal indications through the acquired Kolon Life Science asset. There is no evidence in the source data of proprietary AI/ML capabilities, in-house research platforms, or broader pipeline assets beyond the single acquired therapy. Operating geographies, distribution channels, pricing models, and customer details are not disclosed in the available information.
The business model and revenue mechanics are not evidenced in the source material — no pricing details, distribution arrangements, or revenue figures are disclosed. The company's stated customer segment is healthcare providers and patients suffering from knee osteoarthritis, with the therapy positioned as an innovative biologic treatment for a degenerative joint condition. Given the very thin commercial disclosure, the company's monetization pathway appears to be in early or pre-commercial stages, with the $600 million asset acquisition suggesting either a licensing/royalty-based approach or future direct commercialization following regulatory approval.
Juniper Biologics firmographics
Firmographics- Name
- Juniper Biologics
- Website
- https://juniperbiologics.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Juniper Biologics is a Singapore-based biopharmaceutical company developing novel therapies in oncology, rare diseases, and osteoarthritis, with its current core asset being a gene therapy for knee osteoarthritis acquired from Kolon Life Science.
- Ownership category
- akta.pro rank
Where Juniper Biologics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
Juniper Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Juniper Biologics product offering
Product offeringCore offering
Juniper Biologics is a biopharmaceutical company developing novel therapies in oncology, rare/orphan diseases, and osteoarthritis. Its lead asset is a gene therapy for knee osteoarthritis, acquired from Kolon Life Science in April 2022 in a $600 million transaction. The company operates as a specialty biopharmaceutical entity focused on biologic therapeutics for degenerative joint conditions and high-need disease areas.
Product overview
Juniper Biologics is a biopharmaceutical company operating as a single-product entity focused on gene therapy. The company's primary offering is a gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science in a $600 million deal. As a newer entrant in the biotech space, the company portfolio currently centers on this single acquired therapeutic product.
Differentiator
Problem solved
Functional benefit
Products and services
- Gene Therapy for Knee Osteoarthritis A biologic gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science. Targeted at healthcare providers and patients with degenerative joint conditions who require disease-modifying biologic therapy. The therapy represents Juniper Biologics' lead commercial asset and primary pipeline focus.
Companies that use Juniper Biologics
Customer profileSegments1 record
Ideal customer profiles1 record
Juniper Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Juniper Biologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Kolon Life SciencecoreJuniper Biologics acquired a gene therapy for knee osteoarthritis from Kolon Life Science. The deal was valued at $600 million, representing a significant strategic acquisition of biologic therapeutics technology for treating osteoarthritis.
Scale indicators1 record
Recent moves3 records
Expansion highlights3 records
Juniper Biologics competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Global pharmaceutical incumbent with an established gene therapy portfolio (acquired through Beam Bio and Global Blood). Comparable as a major biopharma player with overlapping modality focus and significant osteoarthritis / musculoskeletal commercial footprint.
- Vertex Pharmaceuticals: Major biopharmaceutical company that has aggressively expanded into gene and cell therapy (e.g., Casgevy approval). Comparable as an established biopharma with significant gene therapy investment and rare disease focus.
- Novartis: Global pharmaceutical leader with approved gene therapies (Kymriah, Zolgensma). Comparable as a large incumbent operating broadly in gene therapy and adjacent biologic modalities.
Regional players
- Samsung Biologics: Korean-based biologics contract development and manufacturing organization. Comparable as a regional (APAC) biologics player serving the broader biopharmaceutical ecosystem, including potential manufacturing partner dynamics for Juniper's gene therapy.
Direct peers
- BioMarin Pharmaceutical: Established biopharmaceutical company with a marketed gene therapy (Roctavian) and pipeline across rare diseases. Comparable as a gene therapy company targeting rare/orphan indications with similar regulatory and commercialization challenges.
- REGENXBIO: Gene therapy platform company developing AAV-based treatments across multiple therapeutic areas including rare diseases. Comparable as a gene therapy technology platform pursuing multiple indications, similar in modality focus to Juniper.
- Sarepta Therapeutics: U.S.-based commercial-stage gene therapy company focused on rare diseases, with multiple approved and clinical-stage gene therapies. Highly comparable as a focused gene therapy company pursuing high-need indications with similar regulatory and commercial dynamics.
- uniQure: Clinical-stage gene therapy company developing treatments for rare and serious diseases. Comparable as a focused gene therapy developer with similar development-stage profile and reliance on platform technology.
- Bluebird Bio: Gene therapy company developing treatments for severe genetic diseases and cancer. Comparable as a single-modality gene therapy developer facing similar clinical, manufacturing, and commercialization risks.
- Kolon Life Science: Korean biopharmaceutical company that developed and transferred the gene therapy for knee osteoarthritis to Juniper Biologics. Closely comparable as the originator of Juniper's core asset and a gene therapy developer with overlapping therapeutic focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Juniper Biologics social profiles
Digital presenceJuniper Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Juniper Biologics leadership team
Management profileNumber of profiles
Profiles1 record
Juniper Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Juniper Biologics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Juniper Biologics
What does Juniper Biologics do?
Juniper Biologics is a biopharmaceutical company developing novel therapies in oncology, rare/orphan diseases, and osteoarthritis. Its lead asset is a gene therapy for knee osteoarthritis, acquired from Kolon Life Science in April 2022 in a $600 million transaction. The company operates as a specialty biopharmaceutical entity focused on biologic therapeutics for degenerative joint conditions and high-need disease areas.
Is Juniper Biologics a public or private company?
Juniper Biologics is a private company. It is classified as unknown and is currently operating.
When was Juniper Biologics founded?
Juniper Biologics was founded in -1. It employs 11 to 50 people.
Where is Juniper Biologics based?
Juniper Biologics is headquartered in Singapore, Singapore, in the Asia region.
Who are Juniper Biologics's main competitors?
Broad incumbents on record are Pfizer, Vertex Pharmaceuticals and Novartis. Samsung Biologics is listed as a regional player. Direct peers are BioMarin Pharmaceutical, REGENXBIO, Sarepta Therapeutics, uniQure, Bluebird Bio and Kolon Life Science.
Does Juniper Biologics have an API?
No public API is recorded for Juniper Biologics.